Literature DB >> 12821276

Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study.

Jasmanda H Wu1, Mary N Haan, Jersey Liang, Debashis Ghosh, Hector M Gonzalez, William H Herman.   

Abstract

PURPOSE: The current study was designed to evaluate the utility of antidiabetic medications in affecting changes in physical and cognitive functioning among older Mexican Americans with diabetes over a 2-year period.
METHODS: A longitudinal analysis with repeated measurements between 1999 and 2001 was performed in a cohort of Mexican Americans, 60 or older, in the SALSA Project. Statistical analysis was conducted using a generalized estimating equation.
RESULTS: For subjects with diagnosed diabetes </= 5 years (N = 381), there was less decline in physical and cognitive functioning over 2 years among subjects on treatment, compared to those without treatment. For subjects with diagnosed diabetes of 5+ years (N = 337), the effect of antidiabetic medications was more significant in preventing the decline in physical and cognitive functioning (ADL: mean in log scale = -0.10, 95% CI = -0.16, -0.04, 3MS: mean = 6.35, 95% CI = 3.23, 9.48). Combination therapy of antidiabetic agents appeared to be more effective than monotherapy in preventing the decline in physical and cognitive functioning for subjects.
CONCLUSIONS: Antidiabetic drugs appear to be useful in alleviating the decline in physical and cognitive functioning among older Mexican Americans with diabetes, especially for those with a longer duration of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821276     DOI: 10.1016/s1047-2797(02)00464-7

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  31 in total

Review 1.  Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies.

Authors:  Efrat Kravitz; James Schmeidler; Michal Schnaider Beeri
Journal:  Endocrinol Metab Clin North Am       Date:  2013-09       Impact factor: 4.741

Review 2.  The association of diabetes and dementia and possible implications for nondiabetic populations.

Authors:  Ramit Ravona-Springer; Michal Schnaider-Beeri
Journal:  Expert Rev Neurother       Date:  2011-11       Impact factor: 4.618

Review 3.  Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 1.

Authors:  Richard Mayeux; Christiane Reitz; Adam M Brickman; Mary N Haan; Jennifer J Manly; M Maria Glymour; Christopher C Weiss; Kristine Yaffe; Laura Middleton; Hugh C Hendrie; Lauren H Warren; Kathleen M Hayden; Kathleen A Welsh-Bohmer; John C S Breitner; John C Morris
Journal:  Alzheimers Dement       Date:  2011-01       Impact factor: 21.566

4.  Importance of Treatment Status in Links Between Type 2 Diabetes and Alzheimer's Disease.

Authors:  Elissa C McIntosh; Daniel A Nation
Journal:  Diabetes Care       Date:  2019-03-04       Impact factor: 19.112

Review 5.  Type 2 diabetes and risk of cognitive impairment and dementia.

Authors:  Rachel A Whitmer
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

6.  Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.

Authors:  Yaomin Chen; Kun Zhou; Ruishan Wang; Yun Liu; Young-Don Kwak; Tao Ma; Robert C Thompson; Yongbo Zhao; Layton Smith; Laura Gasparini; Zhijun Luo; Huaxi Xu; Francesca-Fang Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 7.  Diabetes mellitus and cognitive impairments.

Authors:  Elham Saedi; Mohammad Reza Gheini; Firoozeh Faiz; Mohammad Ali Arami
Journal:  World J Diabetes       Date:  2016-09-15

8.  Guideline-Recommended Medications and Physical Function in Older Adults with Multiple Chronic Conditions.

Authors:  Gail McAvay; Heather G Allore; Andrew B Cohen; Danijela Gnjidic; Terrence E Murphy; Mary E Tinetti
Journal:  J Am Geriatr Soc       Date:  2017-09-14       Impact factor: 5.562

Review 9.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

10.  Predictors of progression of cognitive decline in Alzheimer's disease: the role of vascular and sociodemographic factors.

Authors:  Massimo Musicco; Katie Palmer; Giovanna Salamone; Federica Lupo; Roberta Perri; Serena Mosti; Gianfranco Spalletta; Fulvia di Iulio; Carla Pettenati; Luca Cravello; Carlo Caltagirone
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.